Cureveda Receives SBIR Award to Develop a Novel Treatment for Ulcerative Colitis

Published: Jul 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BALTIMORE--(BUSINESS WIRE)--Cureveda LLC, a company focused on the development of therapeutics targeting the Nrf2 antioxidant pathway, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). Cureveda will use the funds to further research on a novel small molecule Nrf2 activator called VEDA-1209. In collaboration with scientists at Johns Hopkins University, Temple University and Georgia State University, Cureveda will first examine the pharmacokinetic and pharmacodynamics of VEDA-1209 when administered to mice. The results generated will form the basis for selecting a dosing regimen to test VEDA-1209’s efficacy in an animal model of ulcerative colitis. If successful, this project will provide proof of concept supporting further development of VEDA-1209 towards clinical trials in colitis patients.

Help employers find you! Check out all the jobs and post your resume.

Back to news